March 21, 20162Comments

Danger Zone: Rydex Real Estate Funds

Rydex Series Real Estate Funds (RYREX, RYCRX, RYHRX) are in the Danger Zone due to alarmingly poor holdings and overly high fees.

by Kyle Guske II, Senior Investment Analyst, MBA

March 17, 20160Comments

David Trainer On Why Corporate Consulting Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Traditional Corporate Consulting.

by Kyle Guske II, Senior Investment Analyst, MBA

March 15, 20160Comments

Today’s 40% Drop Is Not Enough For Valeant Pharmaceuticals

Valeant Pharmaceuticals (VRX: $36/share) had been in a bit of a limbo lately, as investors awaited the long delayed 4Q15 results. The company finally released its earnings today and the results were to be expected if you heeded our previous warnings.

by Kyle Guske II, Senior Investment Analyst, MBA

March 14, 20160Comments

Danger Zone: Traditional Corporate Consulting

Those consultants who adopt cutting-edge tools will experience more success than those that remain wedded to older, more manual techniques. It’s time we place Traditional Corporate Consulting in the Danger Zone.

by Kyle Guske II, Senior Investment Analyst, MBA

March 10, 20160Comments

David Trainer Explains Why Zillow Group Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Zillow Group (ZG).

by Kyle Guske II, Senior Investment Analyst, MBA

March 7, 20160Comments

Danger Zone: Zillow Group (ZG)

This week’s Danger Zone pick, Zillow Group (ZG), sounds multiple alarms: unusually misleading non-GAAP earnings, overvalued stock, and broken business model.

by Kyle Guske II, Senior Investment Analyst, MBA

March 3, 20160Comments

David Trainer On Why Valeant Phamaceuticals Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Valeant Pharmaceuticals (VRX).

by Kyle Guske II, Senior Investment Analyst, MBA

February 29, 20164Comments

Danger Zone: Valeant Pharmaceuticals (VRX)

We’ve been highlighting the dangers of Valeant for over two years and we do not see them abating. As long as management is incentivized to destroy shareholder value, Valeant is in the Danger Zone.

by Kyle Guske II, Senior Investment Analyst, MBA

February 19, 20160Comments

Danger Zone Performance Worth Noting

The market awards the most value to the companies that give the most back. It punishes those that do not create value. Figure 1 shows how well our Danger Zone picks have done.

by Kyle Guske II, Senior Investment Analyst, MBA

February 18, 20160Comments

David Trainer Explains Why Post Holdings Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Post Holdings (POST).

by Kyle Guske II, Senior Investment Analyst, MBA

February 15, 20162Comments

Danger Zone: Post Holdings (POST)

This week’s Danger Zone focuses on another food products business, similar to recent Danger Zone stocks WhiteWave (WWAV) and Snyder's-Lance (LNCE). Large destruction of shareholder value, skyrocketing debt levels, and insufficient returns on invested capital (ROIC) play a part in Post Holdings (POST: $67/share) landing in the Danger Zone this week.

by Kyle Guske II, Senior Investment Analyst, MBA

February 12, 20160Comments

Price Target Update: Proofpoint (PFPT)

Due to change in market mentality, and in light of the recent downturn in the market, we felt it time to revise our price target for Proofpoint (PFPT)

by Kyle Guske II, Senior Investment Analyst, MBA

February 11, 20160Comments

Price Target Update: Twitter (TWTR)

Due to change in market mentality, and in light of the recent downturn in the market, we felt it time to revise our price target for Twitter (TWTR)

by Kyle Guske II, Senior Investment Analyst, MBA

February 11, 20160Comments

David Trainer Explains Why Pure Storage Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Pure Storage (PSTG).

by Kyle Guske II, Senior Investment Analyst, MBA

February 10, 20160Comments

Price Target Update: Square Inc. (SQ)

Due to change in market mentality, and in light of the recent downturn in the market, we felt it time to revise our price target for Square Inc. (SQ)

by Kyle Guske II, Senior Investment Analyst, MBA

February 10, 20160Comments

Price Target Update: Qlik Technologies (QLIK)

Due to change in market mentality, and in light of the recent downturn in the market, we felt it time to revise our price target for Qlik Technologies (QLIK)

by Kyle Guske II, Senior Investment Analyst, MBA

February 9, 20161Comments

LinkedIn: How Low Can It Go? $20/share

There is a lack of credible research on “just how low can LNKD go?” Our answer has not changed much since we put LinkedIn in the Danger Zone back in August 2013. We think the bottom for this stock is closer to $20/share

by Kyle Guske II, Senior Investment Analyst, MBA

February 8, 20165Comments

Danger Zone: Pure Storage (PSTG)

This week’s Danger Zone hones in on another IPO from 2015 that may have been one of the last to capitalize on the easy money in the market. Post IPO, we believe it won’t take long for investors to realize this company is bleeding cash, has no profits, and faces stiff competition moving forward.

by Kyle Guske II, Senior Investment Analyst, MBA

February 4, 20160Comments

David Trainer On Why WhiteWave Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: WhiteWave Foods (WWAV).

by Kyle Guske II, Senior Investment Analyst, MBA

February 1, 20163Comments

Danger Zone: WhiteWave Foods Company (WWAV)

This week’s Danger Zone focuses on a company with a history of failed acquisitions that operates in a crowded market. Once the rest of the market catches on to the divergence between economic and accounting earnings, this stock is in for a big drop.

by Kyle Guske II, Senior Investment Analyst, MBA

« Older Articles Newer Articles »